Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

VeinRx Inc.

This article was originally published in Start Up

Executive Summary

VeinRx's balloon-controlled venous ablation technology is designed to address both the medical and cosmetic varicose vein markets. It is a single-use, catheter-based product for delivering a sclerosant to the diseased vein. The balloon prevents the chemical from migrating out of the treatment zone. Physicians thus have greater control over both the dosage and the treatment area. There's also a potential safety benefit since the sclerosing agent cannot disperse into the general circulation.

You may also be interested in...



Vein Device Companies Dig Deeper

Vein diseases such as deep vein thrombosis, pulmonary embolism and chronic venous insufficiency have historically been the province of drug therapies, but they shouldn't be, according to the clinical socieities and medical device companies that are trying to create a groundswell in interventional vein treatments. The field is starting to organize: on the clinical side, the first clinical trials ever to pit devices against drugs for DVT are in progress. At the same time, Covidien has drawn attention to the business opportunities in the field by acquiring three companies with venous devices.

New Devices for Varicose Veins

There's nothing even remotely sexy about varicose veins. Yet medical device companies and their investors are starting to view the opportunity for treating these bulging blue leg veins as downright alluring. The recent introduction of minimally invasive technologies, combined with shifting demographics and favorable reimbursements, are fueling talk of blockbuster potential for this hybrid clinical/cosmetic market.

The Long And Short Of Accelerated Approval Accountability In US

The latest accelerated approval withdrawals in the US are milestones for accountability in the program – most notably with the withdrawal of an antimicrobial with confirmatory studies more than a decade overdue.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

MT037435

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel